Xenetic Biosciences Q3 royalty revenue falls 29% ahead of Santersus deal
Overview
US biopharma firm's Q3 royalty revenue fell 29% yr/yr due to prior-year royalty adjustments
Q3 net loss widened to $1.7 mln, with higher costs tied to proposed Santersus deal
Company announced definitive share exchange agreement with Santersus AG, expected to close Q1 2027
Outlook
Company expects proposed Santersus transaction to close in Q1 2027, pending approvals
Combined company anticipates oncology clinical readout in 2027
Company highlights ongoing pivotal sepsis study and planned advancement in lupus for combined entity
Result Drivers
ROYALTY REVENUE DECLINE - Co said Q3 royalty revenue fell due to positive royalty adjustments recognized in the prior-year period under its Takeda sublicense agreement
HIGHER TRANSACTION COSTS - Co attributed increase in general and administrative expenses to legal and financial advisory costs related to proposed Santersus deal
LOWER R&D SPEND - Co said research and development expenses fell due to lower manufacturing development costs
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $1.7 mln |
Reuters Recommended Reads
Nov 12 - SELLAS Life Sciences Q3 net loss widens on higher R&D costs
Nov 12 - Kodiak Sciences Q3 net loss widens as R&D expenses rise
Nov 12 - Pliant Therapeutics Q3 net loss narrows on lower expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)